动脉样硬化中的连接组相关途径和潜在的基于纳米医学的监管策略
Michelle G Santoyo-Suarez1, Adriana G Quiroz Reyes1, Mayela Del-Angel-Martinez2
1Departamento de Bioquímica y Medicina Molecular, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Nanomedicine (London, England)
|November 14, 2025
概括
纳米医学提供了治疗动脉样硬化的新方法,通过准细胞通信网络,如连接体和克鲁佩尔样因子 (KLFs). 这种方法可以实现精确的药物输送和监测,以改善心血管健康.
科学领域:
- 血管生物学 血管生物学
- 纳米医学是一种纳米医学.
- 分子心脏病学分子心脏病学
背景情况:
- 动脉样硬化是导致死亡的主要原因,由血管中复杂的细胞间通信驱动.
- 连接体 (连接体,泛连接体) 和克鲁佩尔样因子 (KLF) 是血管平衡和疾病的关键调节者.
- 目前治疗动脉样硬化有局限性,需要新的治疗策略.
研究的目的:
- 审查连接体和KLFs在动脉样硬化中的作用.
- 探索纳米医学在针对这些诊断和治疗途径方面的潜力.
- 突出转化证据和临床应用的挑战.
主要方法:
- 在PubMed,Scopus和Web of Science中进行了全面的文献审查.
- 关于连xin生物学,KLF信号和纳米医学的实验和转化研究的分析.
- 专注于基于纳米粒子的输送系统用于血管病变.
主要成果:
- 纳米医学平台可以调节连接组和KLF网络,用于动脉样硬化管理.
- 纳米粒子传递系统显示出针对血管病变的小分子,核酸和成像剂的前景.
- 提高纳米治疗药物的特异性和生物可用性的战略正在开发中.
结论:
- 纳米医学与连接组和KLF向干预的融合有可能重新定义动脉样硬化管理.
- 精确的药物输送和实时监测是这种综合方法的关键好处.
- 克服纳米粒子生物相容性,生物分布和安全方面的挑战对于临床转化至关重要.
相关概念视频
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Coronary Artery Disease II: Pathophysiology
332
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
332
Atherosclerosis IV: Nursing Management
337
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
337
Atherosclerosis I: Introduction
738
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
738
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
